India’s Aurobindo Pharma leads race to buy generic drugmaker Zentiva for $5.5 billion, Economic Times reports

(Reuters) -Indian drugmaker Aurobindo Pharma is leading the race to acquire Prague-based generic drugmaker Zentiva from private equity firm Advent International for up to $5.5 billion, the Economic Times reported on Wednesday, citing people aware of the matter.

However, Aurobindo Pharma, in a statement to exchanges, said no binding agreements have been signed by the company’s board.

(Reporting by Kashish Tandon in Bengaluru; Editing by Harikrishnan Nair)